Sunita Parajuli, MD
Infectious Disease · Bronx, NYNPI 1730444605
Payments from drug & device makers
Across 161 payments — averaging $72.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Viiv Healthcare Company$2K
- Janssen Products, LP$2K
- AstraZeneca$1K
- Mimedx Group, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$853
- plus $2K from 19 others
What the payments were for
- Travel & lodging$8627%
- Food & beverage$10,56191%
- Education$2412%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 34 | $2,261 |
| Viiv Healthcare Company | 36 | $1,927 |
| Janssen Products, LP | 18 | $1,899 |
| AstraZeneca | 14 | $1,231 |
| Mimedx Group, Inc. | 4 | $1,170 |
| Teva Pharmaceuticals USA, Inc. | 9 | $853 |
| Lilly USA, LLC | 8 | $336 |
| AbbVie | 2 | $295 |
| Neurocrine Biosciences, Inc. | 2 | $241 |
| Johnson & Johnson(2 entities) | 8 | $176 |
| Alcresta Therapeutics, Inc. | 2 | $167 |
| UCB, Inc. | 2 | $148 |
| EMD Serono, Inc. | 3 | $139 |
| Avanir Pharmaceuticals, Inc. | 2 | $132 |
| Astellas Pharma US Inc | 1 | $129 |
| Urgo Medical North America, LLC | 1 | $125 |
| Abiomed | 1 | $125 |
| Merck | 4 | $99 |
| Smith+Nephew | 4 | $75 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Biogen | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| SK Life Science, Inc. | 1 | $21 |
| Vyera Pharmaceuticals, LLC | 1 | $19 |
| Pfizer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Symtuza$1,657
- LOKELMA$991
- DOVATO$860
- Austedo XR$469
- CABENUVA$370
- Descovy$250
- INGREZZA$241
- Biktarvy$240
- AUSTEDO$228
- DALVANCE$150
- MYRBETRIQ$129
- VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP$125
- DRAWTEX HYDROCONDUCTIVE WOUND DRESSING WITH LEVAFIBER 4X4$125
- UrgoK2$125
- APRETUDE$125
- UZEDY$125
- Fintepla$125
- RELIZORB$125
- FARXIGA$122
- Epclusa$117
How this compares
$11,665 in reported general payments places this provider in the 80th percentile of 799 infectious disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 13 | $60,257 |
| TivicayDolutegravir Sodium | 31 | $37,135 |
| DescovyEmtricitabine/Tenofov Alafenam | 13 | $28,831 |
| IsentressRaltegravir Potassium | 13 | $27,639 |
| Darunavir | 13 | $4,505 |
| Ritonavir | 23 | $3,542 |
| Lamivudine | 12 | $1,920 |
| Eplerenone | 11 | $915 |
| Atorvastatin Calcium | 29 | $847 |
| Levetiracetam | 11 | $624 |
| Pravastatin Sodium | 26 | $501 |
| Gabapentin | 27 | $430 |
| Metformin Hcl | 19 | $345 |
| Metoprolol Succinate | 13 | $327 |
| Tamsulosin Hcl | 15 | $322 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Janssen Products, LPSymtuza | $1,899 | $60,25713 claims |
| Viiv Healthcare CompanyTivicay | $1,927 | $37,13531 claims |
| GileadDescovy | $2,261 | $28,83113 claims |
| MerckIsentress | $99 | $27,63913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 799 infectious disease providers in New York.
Other infectious disease in Bronx
- Barry ZingmanBronx$1.7M
- Norbert BrauBronx$1.6M
- Robert GrossbergBronx$1M
- Paul RiskaBronx$292K
- Eric MeyerowitzBronx$241K
- Julian Torres IsasigaBronx$232K
- Wafaa El SadrNew York$119.1M
- Judith AbergNew York$14.8M
- Stephen ThomasSyracuse$6.2M
- Edward WalshRochester$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.